GH Research PLC (GHRS)
NASDAQ: GHRS · IEX Real-Time Price · USD
11.30
-0.42 (-3.58%)
At close: Apr 23, 2024, 4:00 PM
11.62
+0.32 (2.83%)
After-hours: Apr 23, 2024, 7:57 PM EDT
GH Research Market Cap
GH Research has a market cap or net worth of $587.92 million as of April 23, 2024. Its market cap has increased by 35.50% in one year.
Market Cap
587.92M
Enterprise Value
427.33M
1-Year Change
35.50%
Ranking
Category
Stock Price
$11.30
Market Cap Chart
Since the IPO on June 25, 2021, GH Research's market cap has decreased from $808.33M to $587.92M, a decrease of -27.27%. That is a compound annual growth rate of -10.64%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 23, 2024 | 587.90M | -3.59% |
| Apr 22, 2024 | 609.80M | 6.26% |
| Apr 19, 2024 | 573.90M | -1.43% |
| Apr 18, 2024 | 582.20M | 1.82% |
| Apr 17, 2024 | 571.80M | - |
| Apr 16, 2024 | 571.80M | -6.23% |
| Apr 15, 2024 | 609.80M | 4.74% |
| Apr 12, 2024 | 582.20M | 1.73% |
| Apr 11, 2024 | 572.30M | -0.45% |
| Apr 10, 2024 | 574.90M | -0.36% |
| Apr 9, 2024 | 577.00M | 0.28% |
| Apr 8, 2024 | 575.40M | -0.72% |
| Apr 5, 2024 | 579.60M | 1.08% |
| Apr 4, 2024 | 573.40M | 0.28% |
| Apr 3, 2024 | 571.80M | -0.45% |
| Apr 2, 2024 | 574.40M | -0.36% |
| Apr 1, 2024 | 576.50M | 3.95% |
| Mar 28, 2024 | 554.60M | -0.47% |
| Mar 27, 2024 | 557.20M | -3.43% |
| Mar 26, 2024 | 577.00M | 5.12% |
| Mar 25, 2024 | 548.90M | -2.03% |
| Mar 22, 2024 | 560.30M | 1.69% |
| Mar 21, 2024 | 551.00M | -3.72% |
| Mar 20, 2024 | 572.30M | 1.01% |
| Mar 19, 2024 | 566.60M | 0.75% |
View and export this data all the way back to 2021.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly | 708.86B |
| Novo Nordisk | 560.07B |
| UnitedHealth Group | 448.15B |
| Johnson & Johnson | 361.03B |
| Merck & Co. | 321.87B |
| AbbVie | 300.68B |
| Thermo Fisher | 219.88B |
| AstraZeneca | 219.82B |